All congress activities

This symposium, presented at SSEIM 2024, provides an overview of sepiapterin as a potential treatment for phenylketonuria (PKU) and its implications for patient management

This symposium, presented at SIMD 2024, discusses the results of the Phase 3 APHENITY trial, which investigated the safety and efficacy of sepiapterin in patients with phenylketonuria (PKU)

This poster, presented at SIMD 2024, discusses the preliminary results from the ongoing APHENITY extension study, which evaluates the safety of sepiapterin and its effect on dietary phenylalanine (Phe) consumption in participants with phenylketonuria (PKU)

This poster, presented at SIMD 2024, evaluates the efficacy and safety data of sepiapterin vs placebo in patients with phenylketonuria (PKU) who were receiving sapropterin dihydrochloride at the time of APHENITY study entry

This poster, presented at GMDI 2024, describes the APHENITY extension study phenylalanine (Phe) tolerance assessment design and reports on the compliance rate for 3-day diet diaries among participants

This symposium at SSIEM 2023 discussed the results of the Phase 3 APHENITY trial, investigating the safety and efficacy of sepiapterin in patients with phenylketonuria (PKU)

This infographic distributed at SSIEM 2023 highlights the results of the Phase 3 APHENITY trial, which investigated the safety and efficacy of sepiapterin in patients with phenylketonuria (PKU)